Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Initiator Pharma A/S has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The company's prosecution footprint is currently limited to 1 distinct examiner. This concentration suggests a focused set of claims or a singular application currently under review by the USPTO.
The busiest examiner, MCKOY, QUINCY ANDRE, manages the busiest examiner pending office action. This represents the entirety of the pending workload for the company. With only a single distinct art unit involved, the prosecution strategy is centered on the requirements and feedback of a single examiner within a specific technical field.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCKOY, QUINCY ANDRE | 1 | 68.8% | +39.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17632323 | COMPOUND FOR COMBINATION TREATMENT | MCKOY, QUINCY ANDRE | 157d overdue |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17632323 | COMPOUND FOR COMBINATION TREATMENT | MCKOY, QUINCY ANDRE | 1626 | §103 | Final Rejection | 157d overdue | Pending | Feb 02, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial